AMN107, novel aminopyrimidine inhibitor of Bcr-Abl, is significantly more potent than imatinib mesylate against Philadelphia chromosome positive acute lymphoblastic leukemia cells.

被引：0
|
作者：
Golemovic, M
Beran, M
Giles, F
Manshouri, T
Thomas, D
Cortes, J
Manley, P
Alland, L
Rae, P
Dugan, M
Estrov, Z
Arlinghaus, RB
Kantarjian, H
Verstovsek, S
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Novartis Pharmaceut, Basel, Switzerland
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2737
引用
收藏
页码：748A / 748A
页数：1
相关论文
共 50 条
  • [41] IMMUNOLOGICAL CHARACTERIZATION OF THE TUMOR-SPECIFIC BCR-ABL JUNCTION IN PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA
    VANDENDEREN, J
    VANDERPLAS, D
    MEEUWSEN, T
    ZEGERS, N
    BOERSMA, W
    GROSVELD, G
    VANEWIJK, W
    BLOOD, 1990, 76 (01) : 136 - 141
  • [42] A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with Ph plus chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph plus acute lymphoblastic leukemia (ALL).
    Giles, F. J.
    Larson, R.
    Le Coutre, P.
    Baccarani, M.
    Tavorath, R.
    Alland, L.
    Kantarjian, H. M.
    Hughes, T.
    Ottmann, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 346S - 346S
  • [43] Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
    le Coutre, Philipp
    Ottmann, Oliver G.
    Giles, Francis
    Kim, Dong-Wook
    Cortes, Jorge
    Gattermann, Norbert
    Apperley, Jane F.
    Larson, Richard A.
    Abruzzese, Elisabetta
    O'Brien, Stephen G.
    Kuliczkowski, Kazimierz
    Hochhaus, Andreas
    Mahon, Francois-Xavier
    Saglio, Giuseppe
    Gobbi, Marco
    Kwong, Yok-Lam
    Baccarani, Michele
    Hughes, Timothy
    Martinelli, Giovanni
    Radich, Jerald P.
    Zheng, Ming
    Shou, Yaping
    Kantarjian, Hagop
    BLOOD, 2008, 111 (04) : 1834 - 1839
  • [44] Clinical pharmacokinetics (PK) of AMN107, a novel inhibitor of Bcr-Abl, in healthy subjects and patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) or relapsed/refractory Ph plus acute lymphocytic leukemia (Ph plus ALL).
    Tanaka, C.
    Smith, T.
    Kantarjian, H.
    Giles, F.
    Ottmann, O.
    Bhalla, K.
    Grouss, K.
    Sethuraman, V.
    Thomas, K.
    Schran, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 144S - 144S
  • [45] Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome.
    Druker, BJ
    Sawyers, CL
    Kantarjian, H
    Resta, DJ
    Reese, SF
    Ford, JM
    Capdeville, R
    Talpaz, M
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14): : 1038 - 1042
  • [46] Clinical characteristics and outcomes of adults with Philadelphia chromosome positive and/or bcr-abl positive acute lymphoblastic leukemia: a single center study from China
    Li, Yenan
    Zou, Dehui
    Zhao, Yaozhong
    Mi, Yingchang
    Wang, Jianxiang
    Qiu, Lugui
    LEUKEMIA & LYMPHOMA, 2010, 51 (03) : 488 - 496
  • [47] SERIAL MONITORING OF BCR-ABL BY REAL-TIME POLYMERASE CHAIN REACTION IN NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA TREATED WITH IMATINIB
    Lim, S.
    Joo, Y. D.
    Sohn, B. S.
    HAEMATOLOGICA, 2016, 101 : 350 - 350
  • [48] A novel maxizyme vector targeting a bcr-abl fusion gene induced specific cell death in Philadelphia chromosome-positive acute lymphoblastic leukemia
    Soda, Y
    Tani, K
    Bal, Y
    Saiki, M
    Chen, M
    Izawa, K
    Kobayashi, S
    Takahashi, S
    Uchimaru, K
    Kuwabara, T
    Warashina, M
    Tanabe, T
    Miyoshi, H
    Sugita, K
    Nakazawa, S
    Tojo, A
    Taira, K
    Asano, S
    BLOOD, 2004, 104 (02) : 356 - 363
  • [49] Nilotinib has more effective anti-leukemia propagating cells activity than imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia
    Kong, Y.
    Wu, Y. -L.
    Song, Y.
    Shi, M. -M.
    Hong, D. -L.
    Huang, X. -J.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S489 - S489
  • [50] Results of imatinib mesylate (STI571), a bcr-abl tyrosine kinase inhibitor, in Philadelphia chromosome-positive chronic myelogenous leukemia in blastic phase (Ph plus CML BP).
    Kantarjian, HM
    Cortes, J
    O'Brien, S
    Giles, F
    Albitar, M
    Rios, MB
    Shan, J
    Faderl, S
    Garcia-Manero, G
    Issa, JP
    Thomas, D
    Capdeville, R
    Talpaz, M
    BLOOD, 2001, 98 (11) : 260B - 260B
12345